Format

Send to

Choose Destination
Am J Hypertens. 2004 Nov;17(11 Pt 1):1056-8.

A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension.

Author information

1
Department of Medicine, Renal Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA. townsend@mail.med.upenn.edu

Abstract

BACKGROUND:

Many patients seek complementary medicine treatments like neutraceuticals for common conditions such as hypertension.

METHODS:

We conducted a placebo-controlled prospective randomized crossover study in 10 hypertensive subjects to determine whether a single dose of a hydrolysate of bovine milk protein (designated C12 peptide; low and high dose), either alone or combined with alginic acid (low and high dose), reduced daytime blood pressure (BP), as determined by ambulatory BP monitoring.

RESULTS:

Within the five treatment regimens a significant reduction of 9.2 +/- 3.2 mm Hg in systolic BP at h 6 compared with h 2 occurred on the higher dose of alginic acid (1754 mg) combined with C12 (P = .02). The C12 peptide with the higher dose of alginic acid also showed a significant reduction of 6.0 +/- 2.0 mm Hg in diastolic BP at h 6 compared with h 2 (P = .015).

CONCLUSIONS:

These preliminary data are encouraging and deserve testing in a larger and longer treatment trial.

PMID:
15533734
DOI:
10.1016/j.amjhyper.2004.06.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center